Martin Maier
Vermogen: - $ op 31-05-2026
Vermogen: - $ op 31-05-2026
Martin Maier currently works at Oligonucleotide Therapeutics Society, Inc., as Director, ProQR Therapeutics NV, as Member-Supervisory Board from 2024, and Alnylam Pharmaceuticals, Inc., as Senior Vice President-Oncology.
Dr. Maier received his doctorate degree in 1997 from Eberhard Karls Universität Tübingen.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 18-03-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Directeur/Bestuurslid | 22-05-2024 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2006 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Directeur/Bestuurslid | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Eberhard Karls Universität Tübingen
Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Commercial Services |
ProQR Therapeutics NV
ProQR Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau